Isolation and Characterization of Cross-Neutralizing Human Anti-V3 Single-Chain Variable Fragments (scFvs) Against HIV-1 from an Antigen Preselected Phage Library

Applied Biochemistry and Biotechnology
Rajesh KumarKalpana Luthra

Abstract

Recently conducted human phase- I trials showed protective effect of anti-HIV-1 broadly neutralizing antibodies (bnAbs). The V3 region of the HIV-1 envelope is highly conserved as it is the co-receptor binding site, and is highly immunogenic. Recombinant single-chain antibody fragments (scFvs) can serve as potential tools for construction of chimeric/bispecific antibodies that can target different epitopes on the HIV-1 envelope. Previously, we have constructed a V3 specific human scFv phage recombinant library by a combinational approach of Epstein-Barr virus (EBV) transformation and antigen (V3) preselection, using peripheral blood mononuclear cells (PBMCs), from a subtype C HIV-1 infected antiretroviral naive donor. In the present study, by biopanning this recombinant scFv phage library with V3B (subtype B) and V3C (subtype C) peptides, we identified unique cross reactive anti-V3 scFv monoclonals. These scFvs demonstrated cross-neutralizing activity when tested against subtype A, subtype B, and subtype C viruses. Further, molecular modeling of the anti-V3 scFvs with V3C and V3B peptides predicted their sites of interaction with the scFvs, providing insights for future immunogen design studies. A large collection of such monoc...Continue Reading

References

Sep 26, 1997·FEBS Letters·H DörsamM Little
Dec 14, 2004·AIDS Research and Human Retroviruses·Susan Zolla-PaznerMiroslaw K Gorny
Apr 19, 2005·Applied Biochemistry and Biotechnology·Jean-Philippe GourdineEmilie Smith-Ravin
Jun 28, 2005·Nucleic Acids Research·Dina Schneidman-DuhovnyHaim J Wolfson
Jul 4, 2006·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·C SmulskiM J Levin
Jan 25, 2008·BMC Bioinformatics·Yang Zhang
Jun 25, 2008·Applied Biochemistry and Biotechnology·Qing YuanYuxian Xia
Jul 22, 2008·Bioinformatics·Paolo MarcatiliAnna Tramontano
Aug 19, 2011·Nature·Laura M WalkerPascal Poignard
Mar 13, 2012·Journal of Molecular Recognition : JMR·Gopalan RaghunathanJuan Carlos Almagro
Nov 17, 2012·BMC Biotechnology·Rajesh KumarKalpana Luthra
Oct 12, 2013·Frontiers in Immunology·Inbal Sela-CulangYanay Ofran
Jan 16, 2015·Journal of Virology·Pavel PugachJohn P Moore
Aug 28, 2016·Applied Biochemistry and Biotechnology·Mozafar MohammadiSayyid Nooreddin Faraji
Jan 17, 2017·Nature Medicine·Marina CaskeyFlorian Klein

❮ Previous
Next ❯

Citations

Mar 1, 2020·Drug Discovery Today·Yunfeng LinLei Zhang
Jun 7, 2019·International Journal of Biological Macromolecules·Rajesh KumarKalpana Luthra
Aug 24, 2021·Applied Microbiology and Biotechnology·Hilal Ahmad ParrayRajesh Kumar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.